Free Trial

Fresh Tracks Therapeutics Q4 2023 Earnings Report

Fresh Tracks Therapeutics logo
$0.91 -0.02 (-1.62%)
As of 02/21/2025 02:04 PM Eastern

Fresh Tracks Therapeutics EPS Results

Actual EPS
-$0.20
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Fresh Tracks Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Fresh Tracks Therapeutics Announcement Details

Quarter
Q4 2023
Time
N/A

Conference Call Resources

Fresh Tracks Therapeutics Earnings Headlines

$5,000 DOGE check?
Elon Musk's DOGE agenda just took a very surprising turn... Earlier this week, reports emerged that a portion of the savings DOGE makes in Federal cuts could be funneled back to taxpayers. The media was quick to dub it a DOGE Dividend, with claims circulating that we could all receive a $5,000 check in the mail.
See More Fresh Tracks Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Fresh Tracks Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Fresh Tracks Therapeutics and other key companies, straight to your email.

About Fresh Tracks Therapeutics

Fresh Tracks Therapeutics (NASDAQ:FRTX) does not have significant operations. Previously, the company was engaged in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. Fresh Tracks Therapeutics, Inc. was founded in 2009 and is headquartered in Boulder, Colorado.

View Fresh Tracks Therapeutics Profile

More Earnings Resources from MarketBeat